Genomics

Dataset Information

0

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro


ABSTRACT: HER2-positive (HER2+) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2+ breast cancer cell lines had a higher number of miRNAs with altered expression after treatment with trastuzumab and lapatinib compared to poorly responsive cell lines. To evaluate whether miRNAs can sensitize HER2+ cells to treatment, we performed a high-throughput screen of 1626 miRNA mimics and inhibitors in combination with trastuzumab and lapatinib in HER2+ breast cancer cells. We identified eight miRNA mimics sensitizing cells to targeted treatment, miR-101-5p, mir-518a-5p, miR-19b-2-5p, miR-1237-3p, miR-29a-3p, miR-29c-3p, miR-106a-5p, and miR-744-3p. A higher expression of miR-101-5p predicted better prognosis in patients with HER2+ breast cancer (OS: p=0.0392; BCSS: p=0.0125), supporting the tumor-suppressing role of this miRNA. In conclusion, we have identified miRNAs that sensitize HER2+ breast cancer cells to targeted therapy. This indicates the potential of combining targeted drugs with miRNAs to improve current treatments for HER2+ breast cancers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE163490 | GEO | 2021/05/21

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| EGAS00001005296 | EGA
2019-05-08 | GSE130787 | GEO
2019-05-08 | GSE130786 | GEO
| EGAD00001006844 | EGA
2024-04-09 | PXD047328 | Pride
2019-06-21 | GSE83608 | GEO
2024-06-13 | PXD037998 | Pride
2024-06-13 | PXD037862 | Pride
| EGAD00001006842 | EGA
2024-06-03 | GSE234519 | GEO